Non-<i>CYP2D6</i> Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer

Non-<i>CYP2D6</i> Variants Selected by a GWAS Improve the Prediction of Impaired Tamoxifen Metabolism in Patients with Breast Cancer

A certain minimum plasma concentration of (<i>Z</i>)-endoxifen is presumably required for breast cancer patients to benefit from tamoxifen therapy. In this study, we searched for DNA variants that could aid in the prediction of risk for insufficient (<i>Z</i>)-endoxifen expos...

Full description

Bibliographic Details
Main Authors: Ewa E. Hennig, Magdalena Piątkowska, Krzysztof Goryca, Ewelina Pośpiech, Agnieszka Paziewska, Jakub Karczmarski, Anna Kluska, Elżbieta Brewczyńska, Jerzy Ostrowski
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Journal of Clinical Medicine
Subjects:
Tamoxifen
breast cancer
endoxifen
genome-wide association study
<i>CYP2D6</i> genotype
<i>CYP2D6</i> enhancer
genotyping
SNP microarrays
prediction modeling
threshold level
Online Access:https://www.mdpi.com/2077-0383/8/8/1087

Internet

https://www.mdpi.com/2077-0383/8/8/1087

Similar Items